{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T04:27:35Z","timestamp":1786681655355,"version":"build-2736575974"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsurgicalresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Surgical Research"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jss.2026.02.030","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:14:59Z","timestamp":1774484099000},"page":"186-194","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["A Primer on Restricted Mean Survival Time in Surgical Research"],"prefix":"10.1016","volume":"321","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8421-0686","authenticated-orcid":false,"given":"Xander","family":"Jacquemyn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel Pompeu","family":"S\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Sultan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jss.2026.02.030_bib1","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.14494","article-title":"Characteristics of randomized clinical Trials in surgery from 2008 to 2020: a systematic review","volume":"4","author":"Robinson","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jss.2026.02.030_bib2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/EDE.0b013e3181c1ea43","article-title":"The hazards of hazard ratios","volume":"21","author":"Hern\u00e1n","year":"2010","journal-title":"Epidemiology"},{"key":"10.1016\/j.jss.2026.02.030_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2024.108513","article-title":"Evaluation of the proportional hazards assumption and covariate adjustment methods in comparative surgical observational studies with time-to-event endpoints","volume":"50","author":"Liang","year":"2024","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.jss.2026.02.030_bib4","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1038\/s41416-018-0302-8","article-title":"Assessment of proportional hazard assumption in aggregate data: a systematic review on statistical methodology in clinical trials using time-to-event endpoint","volume":"119","author":"Rulli","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jss.2026.02.030_bib5","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1186\/s12891-021-04379-2","article-title":"Testing the proportional hazards assumption in cox regression and dealing with possible non-proportionality in total joint arthroplasty research: methodological perspectives and review","volume":"22","author":"Kuitunen","year":"2021","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.jss.2026.02.030_bib6","doi-asserted-by":"crossref","DOI":"10.1093\/ejcts\/ezae020","article-title":"Advanced considerations in survival analysis","volume":"65","author":"Carnero-Alc\u00e1zar","year":"2024","journal-title":"Eur J Cardio Thoracic Surg"},{"key":"10.1016\/j.jss.2026.02.030_bib7","first-page":"773","article-title":"Transcatheter or surgical aortic-valve replacement in low-risk patients at 7 years","volume":"0","author":"B","year":"2025","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jss.2026.02.030_bib8","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.surg.2024.04.033","article-title":"Association between type of index complication and outcomes after noncardiac surgery","volume":"176","author":"Chen","year":"2024","journal-title":"Surgery"},{"key":"10.1016\/j.jss.2026.02.030_bib9","article-title":"How restricted mean survival time works","volume":"4","author":"Sarah","year":"2025","journal-title":"NEJM Evid"},{"key":"10.1016\/j.jss.2026.02.030_bib10","article-title":"Breaking free from the hazard ratio: embracing the restricted mean survival time in clinical trials","volume":"2","author":"Larry","year":"2023","journal-title":"NEJM Evid"},{"key":"10.1016\/j.jss.2026.02.030_bib11","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/1471-2288-13-152","article-title":"Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome","volume":"13","author":"Royston","year":"2013","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.jss.2026.02.030_bib12","doi-asserted-by":"crossref","first-page":"278","DOI":"10.6004\/jnccn.2019.7362","article-title":"Quantifying the survival benefits of oncology drugs with a focus on immunotherapy using restricted mean survival time","volume":"18","author":"Rahmadian","year":"2020","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.jss.2026.02.030_bib13","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1002\/sim.9662","article-title":"On assessing survival benefit of immunotherapy using long-term restricted mean survival time","volume":"42","author":"Horiguchi","year":"2023","journal-title":"Stat Med"},{"key":"10.1016\/j.jss.2026.02.030_bib14","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1016\/j.jacc.2019.08.1034","article-title":"Nonproportional hazards for time-to-event outcomes in clinical trials: JACC review topic of the week","volume":"74","author":"Gregson","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jss.2026.02.030_bib15","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s10985-004-4771-0","article-title":"Regression analysis of restricted mean survival time based on pseudo-observations","volume":"10","author":"Andersen","year":"2004","journal-title":"Lifetime Data Anal"},{"key":"10.1016\/j.jss.2026.02.030_bib16","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1177\/0962280209105020","article-title":"Pseudo-observations in survival analysis","volume":"19","author":"Andersen","year":"2009","journal-title":"Stat Methods Med Res"},{"key":"10.1016\/j.jss.2026.02.030_bib17","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1002\/sim.4274","article-title":"The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt","volume":"30","author":"Royston","year":"2011","journal-title":"Stat Med"},{"key":"10.1016\/j.jss.2026.02.030_bib18","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1017\/S0022172400014443","article-title":"The standard error of an estimate of expectation of life, with special reference to expectation of tumourless life in experiments with mice","volume":"47","author":"Irwin","year":"1949","journal-title":"J Hyg"},{"key":"10.1016\/j.jss.2026.02.030_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0150032","article-title":"Difference in restricted mean survival time for cost-effectiveness analysis using individual patient data Meta-Analysis: evidence from a case study","volume":"11","author":"Lueza","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jss.2026.02.030_bib20","doi-asserted-by":"crossref","first-page":"541","DOI":"10.7326\/M19-3286","article-title":"Uses and limitations of the restricted mean survival time: illustrative examples from cardiovascular outcomes and mortality trials in type 2 diabetes","volume":"172","author":"Kloecker","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jss.2026.02.030_bib21","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1111\/biom.13237","article-title":"On the empirical choice of the time window for restricted mean survival time","volume":"76","author":"Tian","year":"2020","journal-title":"Biometrics"},{"key":"10.1016\/j.jss.2026.02.030_bib22","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1177\/1536867X1501500409","article-title":"Estimating the treatment effect in a clinical trial using difference in restricted mean survival time","volume":"15","author":"Patrick","year":"2015","journal-title":"Stata J"},{"key":"10.1016\/j.jss.2026.02.030_bib23","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12874-021-01213-0","article-title":"Estimating restricted mean survival time and expected life-years lost in the presence of competing risks within flexible parametric survival models","volume":"21","author":"Mozumder","year":"2021","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.jss.2026.02.030_bib24","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1001\/jama.2025.13655","article-title":"How to communicate medical numbers","volume":"334","author":"Zikmund-Fisher","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.jss.2026.02.030_bib25","doi-asserted-by":"crossref","first-page":"270","DOI":"10.7326\/M14-0295","article-title":"Evidence-Based risk communication","volume":"161","author":"Zipkin","year":"2014","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jss.2026.02.030_bib26","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1177\/0272989X14526305","article-title":"Communicating relative risk changes with baseline risk: presentation format and numeracy matter","volume":"34","author":"Nicolai","year":"2014","journal-title":"Med Decis Making"},{"key":"10.1016\/j.jss.2026.02.030_bib27","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1136\/bmj.317.7156.468","article-title":"Time to event (survival) data","volume":"317","author":"Altman","year":"1998","journal-title":"BMJ"},{"key":"10.1016\/j.jss.2026.02.030_bib28","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1161\/CIRCULATIONAHA.106.614859","article-title":"Survival methods","volume":"115","author":"Rao","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jss.2026.02.030_bib29","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1136\/bmj.317.7172.1572","article-title":"Survival probabilities (the Kaplan-Meier method)","volume":"317","author":"Bland","year":"1998","journal-title":"BMJ"},{"key":"10.1016\/j.jss.2026.02.030_bib30","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.6498","article-title":"Assessment of median and mean survival time in cancer clinical trials","volume":"6","author":"Das","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jss.2026.02.030_bib31","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1136\/bmj.328.7447.1073","article-title":"The logrank test","volume":"328","author":"Bland","year":"2004","journal-title":"BMJ"},{"key":"10.1016\/j.jss.2026.02.030_bib32","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s12874-019-0749-1","article-title":"Are non-constant rates and non-proportional treatment effects accounted for in the design and analysis of randomised controlled trials? A review of current practice","volume":"19","author":"Jachno","year":"2019","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.jss.2026.02.030_bib33","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1001\/jamaoncol.2022.2666","article-title":"Log-Rank Test vs MaxCombo and difference in restricted mean survival time tests for comparing survival under nonproportional hazards in immuno-oncology trials: a systematic review and meta-analysis","volume":"8","author":"Mukhopadhyay","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jss.2026.02.030_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2023.107165","article-title":"A comparative study to alternatives to the log-rank test","volume":"128","author":"Dormuth","year":"2023","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.jss.2026.02.030_bib35","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life-tables","volume":"34","author":"Cox","year":"1972","journal-title":"J R Stat Soc Ser B (Methodological)"},{"key":"10.1016\/j.jss.2026.02.030_bib36","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/biomet\/68.1.105","article-title":"Estimation of the average hazard ratio","volume":"68","author":"Kalbfleisch","year":"1981","journal-title":"Biometrika"},{"key":"10.1016\/j.jss.2026.02.030_bib37","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1177\/1536867X0900900206","article-title":"Further development of flexible parametric models for survival analysis","volume":"9","author":"Lambert","year":"2009","journal-title":"Stata J"},{"key":"10.1016\/j.jss.2026.02.030_bib39","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1002\/sim.1203","article-title":"Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects","volume":"21","author":"Royston","year":"2002","journal-title":"Stat Med"},{"key":"10.1016\/j.jss.2026.02.030_bib40","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1002\/sim.4780111409","article-title":"The accelerated failure time model: a useful alternative to the cox regression model in survival analysis","volume":"11","author":"Wei","year":"1992","journal-title":"Stat Med"},{"key":"10.1016\/j.jss.2026.02.030_bib41","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ijrobp.2025.02.006","article-title":"Challenges in interpreting survival metrics in clinical trials: the utility of restricted mean survival analyses","volume":"122","author":"Averbuch","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jss.2026.02.030_bib42","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1111\/jgs.17195","article-title":"Restricted mean survival time versus conventional measures for treatment decision-making","volume":"69","author":"Kim","year":"2021","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.jss.2026.02.030_bib43","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S2213-2600(24)00119-X","article-title":"Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial","volume":"12","author":"Lim","year":"2024","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jss.2026.02.030_bib44","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1001\/jamasurg.2021.5104","article-title":"Laparoscopic vs open distal gastrectomy for locally advanced gastric cancer: Five-Year outcomes from the CLASS-01 randomized clinical trial","volume":"157","author":"Huang","year":"2022","journal-title":"JAMA Surg"},{"key":"10.1016\/j.jss.2026.02.030_bib45","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1177\/1740774520976576","article-title":"Are restricted mean survival time methods especially useful for noninferiority trials?","volume":"18","author":"Boris","year":"2021","journal-title":"Clin Trials"},{"key":"10.1016\/j.jss.2026.02.030_bib46","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1161\/CIRCULATIONAHA.119.040680","article-title":"Using the restricted mean survival time difference as an alternative to the hazard ratio for analyzing clinical cardiovascular studies","volume":"140","author":"McCaw","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jss.2026.02.030_bib47","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1001\/jamacardio.2017.2922","article-title":"Restricted mean survival time as a measure to interpret clinical trial results","volume":"2","author":"Kim","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jss.2026.02.030_bib48","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1016\/S0140-6736(15)60308-7","article-title":"5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial","volume":"385","author":"Mack","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jss.2026.02.030_bib49","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1016\/S0140-6736(15)60290-2","article-title":"5-year outcomes of transcatheter aortic valve replacement compared with standard treatment for patients with inoperable aortic stenosis (PARTNER 1): a randomised controlled trial","volume":"385","author":"Kapadia","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jss.2026.02.030_bib50","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1056\/NEJMoa1909406","article-title":"Five-Year outcomes after PCI or CABG for left main coronary disease","volume":"381","author":"W","year":"2019","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jss.2026.02.030_bib51","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1056\/NEJMoa1602001","article-title":"Coronary-artery bypass surgery in patients with ischemic cardiomyopathy","volume":"374","author":"Velazquez","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jss.2026.02.030_bib52","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1056\/NEJMoa1100356","article-title":"Coronary-artery bypass surgery in patients with left ventricular dysfunction","volume":"364","author":"Velazquez","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jss.2026.02.030_bib53","doi-asserted-by":"crossref","first-page":"3655","DOI":"10.1002\/ehf2.13731","article-title":"Within trial comparison of survival time projections from short-term follow-up with long-term follow-up findings","volume":"9","author":"Ferreira","year":"2022","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jss.2026.02.030_bib54","article-title":"Coronary artery bypass surgery improves restricted mean survival time in patients with ischemic cardiomyopathy","volume":"54","author":"Reinhardt","year":"2025","journal-title":"Am Heart J Plus"},{"key":"10.1016\/j.jss.2026.02.030_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2025.133269","article-title":"Early aortic valve replacement versus conservative management in asymptomatic severe aortic stenosis: Meta-analysis of time-to-event data of randomized controlled trials","volume":"432","author":"Jacquemyn","year":"2025","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jss.2026.02.030_bib56","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12874-016-0137-z","article-title":"Bias and precision of methods for estimating the difference in restricted mean survival time from an individual patient data meta-analysis","volume":"16","author":"Lueza","year":"2016","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.jss.2026.02.030_bib57","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.0809","article-title":"Invasive treatment strategy in adults with Frailty and Non\u2013ST-Segment elevation myocardial infarction: a secondary analysis of a randomized clinical trial","volume":"7","author":"Sanchis","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jss.2026.02.030_bib58","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1186\/s12874-020-01098-5","article-title":"Dynamic RMST curves for survival analysis in clinical trials","volume":"20","author":"Liao","year":"2020","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.jss.2026.02.030_bib59","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12874-016-0110-x","article-title":"Augmenting the logrank test in the design of clinical trials in which non-proportional hazards of the treatment effect may be anticipated","volume":"16","author":"Royston","year":"2016","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.jss.2026.02.030_bib60","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1177\/1740774520905563","article-title":"Designing clinical trials with (restricted) mean survival time endpoint: practical considerations","volume":"17","author":"Eaton","year":"2020","journal-title":"Clin Trials"},{"key":"10.1016\/j.jss.2026.02.030_bib61","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1177\/1536867X1001000306","article-title":"Projection of power and events in clinical trials with a time-to-event outcome","volume":"10","author":"Patrick","year":"2010","journal-title":"Stata J"}],"container-title":["Journal of Surgical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022480426000843?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022480426000843?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T03:38:25Z","timestamp":1786678705000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022480426000843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":60,"alternative-id":["S0022480426000843"],"URL":"https:\/\/doi.org\/10.1016\/j.jss.2026.02.030","relation":{},"ISSN":["0022-4804"],"issn-type":[{"value":"0022-4804","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Primer on Restricted Mean Survival Time in Surgical Research","name":"articletitle","label":"Article Title"},{"value":"Journal of Surgical Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jss.2026.02.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}